FRZB is an antagonist of the Wnt pathway, and the downregulation of FRZB in MSCs leads to β-catenin activation, which promotes the onset of MDS, and this is more obvious in HR-MDS (45). This evidence concerns the gene FRZB and myelodysplastic syndrome.